Biotechnology Analyst Watsek, along with Michael Skynner, PhD, Chief Technology Officer of Bicycle Therapeutics (BCYC) discuss Radionuclide Conjugates on an Analyst/Industry conference call to be held on December 4 at 11 am. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
- Bicycle Therapeutics initiated with an Equal Weight at Stephens
- Stephens sees ‘uphill battle’ for Bicycle Therapeutics, starts at Equal Weight
- Bicycle Therapeutics Faces Strategic Risks from Concentrated Shareholder Influence
- Bicycle Therapeutics: Promising Q3 Results and Business Progress